Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2009 Mar 10

PMID 19269363

Citations 919

Authors

Ji Luo

Nicole L Solimini

Stephen J Elledge

Affiliations

Soon will be listed here.

Abstract

Cancer is a complex collection of distinct genetic diseases united by common hallmarks. Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis. We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells. In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets. Finally, we discuss the path ahead to therapeutic discovery and provide theoretical considerations for combining orthogonal cancer therapies.

Citing Articles

LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models.

Podolski-Renic A, Chigriai M, Jovanovic Stojanov S, Grozdanic M, Lupsic E, Nikolic I Pharmaceutics. 2025; 17(2).

PMID: 40006556 PMC: 11859366. DOI: 10.3390/pharmaceutics17020189.

Intratumour oxidative hotspots provide a niche for cancer cell dissemination.

Ueda Y, Kiyonaka S, Selfors L, Inoue K, Harada H, Doura T Nat Cell Biol. 2025; 27(3):530-543.

PMID: 39984655 DOI: 10.1038/s41556-025-01617-w.

Advances in sporadic brain arteriovenous malformations: Novel genetic insights, innovative animal models, and emerging therapeutic approaches.

Ueki Y, Naylor R, Ghozy S, Thirupathi K, Rinaldo L, Kallmes D J Cereb Blood Flow Metab. 2025; :271678X251319913.

PMID: 39948029 PMC: 11826813. DOI: 10.1177/0271678X251319913.

HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms.

Ghai S, Shrestha R, Su K Front Cell Dev Biol. 2025; 12:1500880.

PMID: 39850800 PMC: 11754285. DOI: 10.3389/fcell.2024.1500880.

Sundararajan R, Hegde S, Panda A, Christie J, Gadewal N, Venkatraman P Commun Biol. 2025; 8(1):55.

PMID: 39814910 PMC: 11735796. DOI: 10.1038/s42003-024-07432-7.

References

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

Selivanova G, Wiman K . Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 2007; 26(15):2243-54. DOI: 10.1038/sj.onc.1210295. View

Dickins R, McJunkin K, Hernando E, Premsrirut P, Krizhanovsky V, Burgess D . Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet. 2007; 39(7):914-21. PMC: 4595852. DOI: 10.1038/ng2045. View

Strebhardt K, Ullrich A . Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30. DOI: 10.1038/nrc1841. View

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

Quintas-Cardama A, Kantarjian H, Cortes J . Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007; 6(10):834-48. DOI: 10.1038/nrd2324. View

10.

Ashwell S, Zabludoff S . DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res. 2008; 14(13):4032-7. DOI: 10.1158/1078-0432.CCR-07-5138. View

11.

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

12.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

13.

Weaver B, Cleveland D . Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005; 8(1):7-12. DOI: 10.1016/j.ccr.2005.06.011. View

14.

Hartwell L, Kastan M . Cell cycle control and cancer. Science. 1994; 266(5192):1821-8. DOI: 10.1126/science.7997877. View

15.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

16.

Verdine G, Walensky L . The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007; 13(24):7264-70. DOI: 10.1158/1078-0432.CCR-07-2184. View

17.

Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C . Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006; 444(7119):638-42. DOI: 10.1038/nature05327. View

18.

Peggs K, Quezada S, Allison J . Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008; 224:141-65. DOI: 10.1111/j.1600-065X.2008.00649.x. View

19.

Wells J, McClendon C . Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-9. DOI: 10.1038/nature06526. View

20.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M . Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-4. DOI: 10.1126/science.1071489. View